INTRODUCTION 42
Transgenic rodent (TGR) mutation reporter models have enabled unprecedented 43 insights into spontaneous and chemically induced mutagenesis 1 . Studies of over 200 chemicals, 44 including more than 90 carcinogens, have demonstrated that TGR models offer high sensitivity 45
and specificity for identifying mutagenic carcinogens 1,2 . One of the most commonly used TGR 46 models is the MutaMouse whose genome was recently sequenced 3 . The MutaMouse harbors 47 ~29 copies of the bacterial lacZ transgene on each copy of chromosome 3 4 . This is a neutral, 48 transcriptionally-inert reporter gene carried on a shuttle vector that can be recovered from any 49 cell type and transfected into a bacterial host to detect somatic or germline mutations that 50 occurred in vivo 5,6 . A major advantage of TGR models is the possibility to sequence mutants in 51 order to characterize mutation spectra. This information is necessary to understand mutational 52 mechanisms associated with mutagen exposure and response in different tissues, life stages 53 genetic backgrounds or other contexts. Advances in next-generation sequencing (NGS) 54 technologies have enabled rapid and accurate characterization of TGR mutants 7,8 , and 55 integrated TGR-NGS approaches have been used to sequence thousands of mutations 8,9 at a 56 fraction of the cost of whole genome sequencing. Thus, TGR-NGS approaches currently 57 provide a unique methodology for simultaneously assessing the magnitude of the mutagenic 58 response and mutation spectrum to inform underlying mechanisms. 59
Somatic mutation analysis by NGS has greatly advanced our understanding of the 60 mutational processes operating in human cancers. Algorithms have been developed to mine the 61 extensive database of single nucleotide variations (SNVs) in cancer genomes to identify 62 mutational signatures contributing to individual cancers 10, 11, 12 . These signatures represent a 63 computationally derived prediction of the relative frequencies of mutation types induced by 64 processes that contribute to all observed mutations within The Cancer Genome Atlas datasets 65 (TCGA; https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga). 66
As opposed to standard mutation spectrum characterization that simply describes the frequency 67 of individual nucleotide changes, mutational signatures incorporate flanking nucleotide context. 68
Originally, 30 mutational signatures from 40 different cancer types were identified and reported 69 in the Catalogue of Somatic Mutations in Cancer (COSMIC) database 13, 14 . This database was 70 recently expanded to include 71 cancer types and 77 signatures, including 49 single base 71 substitution (SBS) signatures, 11 doublet base substitution (DBS) signatures, and 17 small 72 insertion and deletion (ID) signatures 15 . Each signature encompasses 96 possible mutation 73 types (i.e., 6 possible base pair alterations × 4 different 5' bases × 4 different 3' bases). Many of 74 these signatures have been attributed to endogenous processes, but chemical mutagens also 75 play a major contributing role in certain signatures 16 . For example, SBS 4 signature is observed 76 in lung cancer and has been attributed to tobacco smoke 16, 17 . This signature has been 77 recapitulated by exposing murine embryo fibroblasts to benzo[a]pyrene (BaP) 18, 19 , a major 78 mutagenic component of tobacco smoke. However, several of the mutational signatures 79 currently have no known endogenous or exogenous causative agents 17 ; thus, identification of 80 exogenous environmental exposures that contribute to these mutational signatures may aid in 81 elucidating carcinogenic mechanisms. 82
The pattern of mutations observed in a fully developed cancer is a composite of the 83 signature of the molecular initiating events in the early stages of tumour formation and 84 signatures arising as a result of genomic instability in the evolving tumour 20 . For example, a 85 tumour that originates in the lung of a smoker will have a mutational fingerprint that is caused 86 primarily by DNA damage induced by the many mutagenic compounds found in tobacco 87 smoke 21 . In addition, the person's age at the time of tumour formation will also determine the 88 contribution of "clock-like" signatures, caused by lifetime DNA replication, to the fingerprint of 89 the tumour 22 . There is now compelling evidence that analysis of the spectrum of mutations in a 90 cancer can provide clues to past environmental exposures that contributed to the development 91 of the cancer 23, 24 . Implicit in this is that the exposure signature should be present in the normal 92 tissue before the carcinogenic process becomes apparent. Indeed, previous studies have 93 demonstrated that mutational signatures observed in aflatoxin-induced cancers are observed in 94 normal tissues long before tumour formation 25, 26 . Recent work in vivo 27 and in vitro 28 has shown 95 that chemical-specific signatures detected shortly after exposure match signatures seen in 96 human cancers. Thus, characterization of short-term mutational signatures in non-tumour 97 tissues is a valuable approach to elucidate human-relevant mechanisms of carcinogenesis. 98
In this study, we used TGR-NGS to characterize mutations induced by four established 99 mutagens to determine if these mutation profiles inform carcinogenic mechanisms within 100 COSMIC signatures. For this purpose, we chose four chemicals with varying mutagenic 101 potencies, mode of action, and carcinogenic classification (as determined by the International 102
Agency for Research on Cancer): one known class 1 carcinogen, BaP; two probable class 2 103 carcinogens including N-ethyl-N-nitrosourea (ENU) and procarbazine (PRC); and one class 3 104 chemical with inadequate information to be classified, triethylenemelamine (TEM). MutaMouse 105 males were exposed by gavage to the chemicals or solvent for 28 days and DNA was collected 106 from bone marrow for analysis. To further compare lacZ mutation spectra and COSMIC 107 signatures, published Sanger sequencing data from 17 studies involving eight mutagens were 108 also examined ( Supplementary Table S1 ). These studies include data from mice exposed to 109 electromagnetic radiation 29, 30, 31, 32, 33 , alkylating agents and adduct-forming agents 34,35,36,37,38,39,40 , 110 and a nitrogenous base analog 41 . Data from control animals in these studies and 111 others 42, 43, 44, 45, 46 were also included to generate a background mutation signature. Using lacZ-112 derived mutation data, we validated COSMIC signatures with proposed aetiologies through the 113 identification of the expected signatures in the relevant exposure groups. We argue that 114 analysis of COSMIC signatures observed in exposed animals can be used to generate or test 115 hypotheses of mutagenic mechanisms associated with human mutational signatures of 116 unknown etiology. 117
118

RESULTS
119
We used mutation spectra generated in-house for four chemicals (BaP, ENU, PRC, and 120 TEM) and vehicle matched controls, and published data from eight agents, including BaP and 121 ENU ( Supplementary Table S1 ) and their matched controls, to query the COSMIC database 122 and elucidate the role of environmental mutagens in cancer development. The overall 123 experimental design is summarized in Figure 1 . 124
Mutation spectra were generated from plaques collected during experiments aimed at 125 sequenced in the Controls, BaP, PRC, ENU, and TEM groups, respectively. These sequenced 144 mutants represented 512, 1,547, 120, 419, and 153 independent mutations in the five groups, 145 respectively. 146
In the lacZ gene, there are 3,096 positions × 3 possible substitutions at each position for 147 a total of 9,288 possible unique SNV events; however, not all of these can be detected using a 148 functional assay, since many result in silent mutations. Sequencing mutants from the different 149 groups identified 891 unique SNVs, 338 of which overlapped between two or more groups 150 (Supplementary Figure S1 ). Specific to each group, there were 55, 377, 14, 85, and 22 unique 151 SNVs for Controls, BaP, PRC, ENU, and TEM, respectively ( Supplementary Table S3 ). The 152 mutations detected in this study are limited almost exclusively to point mutations and small 153 indels (1-21 bp), as large deletions are infrequently recovered during packaging of the DNA for 154 the lacZ assay 8 . 155
The mutation spectra of the four chemicals were significantly different from the control 156 mutation spectrum ( Figure 2 ; P ≤ 0.0008). The COSMIC convention is to represent mutations 157 based on pyrimidine changes; thus, we present our mutation spectrum using the same 158 convention. The main spontaneous mutation is represented by C>T transitions, which are 159 thought to arise through spontaneous mechanisms such as deamination of methylated 160 cytosines 49 . Although there may be proportional declines in specific mutations relative to 161 controls ( Figure 2) , all of the chemicals tested in this study, with the exception of TEM, 162 increased the mutation frequency of substitutions (e.g., C>T; Supplementary Figure S2 ). 163
The mutation spectra of BaP and ENU are consistent with previous observations. BaP 164 exposure caused cytosine transversions and indels ( Figure 2 ), mainly C>A SNVs, consistent 165 with the formation of bulky DNA adducts mostly at the N2 of guanine 8 . ENU induced T>A 166 mutations consistent with alkylation of thymine, specifically O 2 -and O 4 -ethyl thymine 50, 51 . We 167 found that PRC induced T>A mutations and, to a lesser extent T>C mutations, which is 168 consistent with the pattern of mutations that was observed in an endogenous gene 52 . The 169 mutation spectrum of TEM was significantly different from controls, but there were no significant 170 changes in specific SNV types. Instead, this effect is mainly driven by the higher proportion of 171 TEM-induced single nucleotide insertions compared to control animals. TEM also induced the 172 highest proportion of >1bp indels among all chemicals tested ( Figure 2) . 173 174
Identification of COSMIC Signatures Using lacZ Mutations 175
We explored the use of the lacZ sequence to obtain mutational signatures associated 176 with human cancers. Although the COSMIC database (version 3) includes also DBS and ID 177 signatures, we focused on SBS signatures because the lacZ assay detects almost exclusively 178 these types of events. We first divided each trinucleotide frequency in the lacZ transgene 179 Figure S3 ). We then used the lacZ 181 sequencing data from NGS and Sanger experiments in COSMIC format (Supplementary Figure  182 S4) to identify which of the normalized signatures were most closely associated with the 183 mutation spectrum of each agent. This initial analysis showed that mutational signatures in 184 human cancers that have been associated with specific mutagenic exposures were enriched in 185 the lacZ mutation profiles for the appropriate agent tested in this study ( Figure 4 ). For example, 186 the UVB 29, 31 and sunlight 30 mutation profiles had very strong correlations (Pearson's coefficient 187 = 0.93-0.98) with the SBS 7a signature, which is observed in human skin cancers. Similarly, the 188 BaP mutation profile showed a strong correlation with several signatures including SBS 4 189 (Pearson's coefficient = 0.76), which is observed in tobacco smoke-induced cancers. In total, 190 there were six SBS signatures that had a Pearson's coefficient greater than 0.8 with the 191 mutation spectra generated from sequenced lacZ mutations ( Figure 4) . 192
Next, we used each of the agent-generated mutation data to simultaneously query the 193 entire COSMIC SBS database to establish which of the signatures contributed to the observed 194 spectra (Supplementary Figure S5 ). This process was conducted as described in steps 7-9 of 195 Figure 1. Prior to this analysis, we used control mutation data to generate an in vivo background 196 signature ( Figure 5 ) to account for the fact that some mutations present in the exposure groups 197 are also spontaneous in origin rather than specific to the mutagen tested. This is especially true 198 for weak mutagens. As shown in Figure 5 , the in vivo background signature is enriched primarily 199 in C>T mutations, and to a lesser extent C>A mutations, and this was consistent among all 200 tissues that contributed to the control signature (Supplementary Figure S6 ). Inclusion of the 201 control signature improved the association between reconstructed signatures and mutation data 202 by as much as 26% ( Figure 6 ) and eliminated five of the weakly associated signatures 203 (Supplementary Figure S7 ). Finally, application of stringent filtering criteria (see Methods) 204
revealed the association of nine COSMIC SBS signatures with mutation data from the various 205 exposure groups ( Figure 6 ). 206
The signatures produced by the three electromagnetic radiations (i.e., UVB, sunlight, 207 and X-rays) appear to be broadly similar when visually assessing individual SBS signature 208 heatmaps ( Figure 4 ). However, we found that different mutational processes contribute to each 209 signature. Specifically, SBS 2 and the control signature each explained 33% of the UVB 210 mutation profile; SBS 2 and SBS 7a each explained 27% of the sunlight data ( Figure 6 ); and the 211 mutation spectrum associated with X-rays, which induces large deletions rather than point 212 mutations (56 indels ranging from 1-437 bp vs 35 SNVs 33 ), was most associated with the SBS 213 10b signature (49%). 214
For the bulky adduct group, the mutation spectrum of BaP revealed mutational 215 processes characteristic of SBS 4 (36%) and SBS 39 (27%) signatures. SBS 4 is most notably 216 associated with tobacco-smoke induced cancer 16 , while SBS 39 is one of the new signatures 217 that currently does not have a proposed etiology. No SBS signature was associated with the 218 mutation profile of NDBzA and the control signature explained 53% of the mutation profile of this 219
agent. 220
Analysis of the alkylating agent exposure group revealed that SBS 11 and SBS 30 221 signatures were associated with N-nitrosodimethylamine (NDMA) mutation data 34 and explained 222 37% and 50% of the mutations, respectively. SBS 11 has previously been linked to exposures 223 to the methylating agents temozolomide and N-methyl-N'-nitro-N-nitrosoguanidine 17, 19 . SBS 30 224 is hypothesized to be associated with defects in base excision repair. No SBS signatures were 225 associated with the mutation profiles of ENU or PRC while the control signature explained 36% 226 and 42% of the mutation profiles of these two chemicals, respectively. 227
There were limited data available for nitrogenous base analogs. Data were only 228 obtained from mice exposed to 5-(2-chloroethyl)-2-deoxyuridine (CEDU) 41 , a uridine analog. 229
This included only 14 characterized mutants from bone marrow, 13 of which were T>C 230 mutations. Consequently, 80% of the data were explained by the SBS 26 signature, which 231 exhibits a bias for these types of substitutions. 232 TEM had a SNV mutation spectrum that was similar to controls ( Figure 2 ). Nevertheless, 233
we found that SBS 40 contributed to 32% of the TEM data, which was higher than the 20% that 234
can be attributed to the control signature. There is currently no known etiology for the SBS 40 235
signature. 236
Overall, the reconstructed signatures had very strong Pearson's coefficients (0.84 -0.98) 237
for six of the agents and strong coefficients (0.63 -0.74) for four agents with the respective lacZ-238 generated mutation profiles ( Figure 6 and Supplementary Figure S4 ). 239 240 DISCUSSION 241 We show that in vivo NGS-TGR data can be used to extract mutagenic mechanisms that 242 may contribute to human cancers through application of COSMIC signature analysis. We also 243
show that such analyses are improved through the inclusion of a background mutational 244 signature (i.e., control signature) that reflects spontaneous mutations resulting from endogenous 245 processes. Analysis of induced mutations in mouse tissues following exposures to 10 mutagenic 246 agents (two sequenced by NGS, six sequenced by the Sanger method, and two by both) 247 revealed high concordance between the expected mutagenic mode of action and the relevant 248 COSMIC signature. The data suggest that our approach can be used to: (i) test if TGR mutation 249 spectra support hypotheses that COSMIC signatures are attributed to particular mutagenic 250 exposures, and (ii) generate hypotheses about the mutagenic mechanisms underlying human 251 cancers through identifying enriched COSMIC signatures in TGR mutation spectra. 252
A large portion of mutations collected from weak mutagens are spontaneous rather than 253 chemically induced. Thus, we developed a background signature derived from our empirical 254 control data that can be integrated with COSMIC signatures to reduce the noise attributable to 255 spontaneous mutation patterns. This in vivo control signature is a unique feature of our study, 256 as there is currently no 'background' COSMIC signature and no in vivo control signature is 257 reported in a recent study that generated chemical-specific signatures in vivo using a different 258 approach 27 . Our results show that C>T transitions are the most common spontaneous mutations 259 in vivo ( Figure 5 ) and this was consistent among all tissues analyzed (Supplementary Figure 6) . 260
C>T transitions at CpG sites are known hotspots of mutation due to spontaneous deamination 261 of cytosine 49 . Previous work using bisulfite sequencing has shown that CpG sites in lacZ are 262 heavily methylated, and CpG flanked by a 5' pyrimidine were most likely to have C>T base 263 substitutions 46 . This is supported by our control data: the most prevalent spontaneous mutations 264
were C>T at CCG, and, the third most prevalent were C>T mutations at TCG ( Figure 5 ). Thus, 265 our background control signature is consistent with expectations.
An in vitro background signature was recently reported 28 ; however, the correlation 267 between the two control signatures is modest (Pearson's coefficient = 0.45) because, at 268 variance with our results, the in vitro control signature is enriched for C>A mutations. 269
Spontaneous deamination of cytosine is also the most likely reason for C>A transversions and 270 seem to be the most common spontaneous mutation in vitro 53 . This suggests that the same type 271 of event, i.e., cytosine deamination, can results in different outcomes, i.e., C>T versus C>A 272 mutations, depending on the physiological context. 273
Application of the control signature ( Figure 5 ) and stringent statistical analysis identified 274 nine SBS signatures that were associated with the lacZ SNVs induced by the investigated 275 exposures. Two major outcomes from this analysis are: 1) mutation profiles for some of the 276 tested agents were highly enriched for COSMIC signatures from cancers where the agents are 277 known etiological factors (e.g., UV for skin cancer and BaP for tobacco-related cancers); and, 2) 278 a few lacZ mutation profiles were associated with a variety of signatures of unknown aetiologies. 279
This raises the question of whether the mutagenic mechanisms of these prototype agents are 280 determinants of the signatures. 281
We identified the SBS 2, SBS 7a, and SBS 10b signatures as important contributors to 282 the mutagenic mechanisms of all three electromagnetic radiation agents investigated (i.e., X-283 ray, UVB, and sunlight). SBS 2 has been observed in ~14% of cancer samples and is present in 284 22 cancer types but is most often found in cervical and bladder cancers 14, 17 . In this study, the 285 signature was most strongly associated with UV skin exposure, representing 33-27% of 286 mutations in exposed animals. Mechanistically, cytosine deamination is accelerated by UV 287 exposure 54 ; thus, it is possible that we observed SBS 2 in this study because of UV-dependent 288 cytosine deamination. However, SBS 2 is not observed in skin cancers 17 . This suggests that 289 mutations arising from UV-dependent cytosine deamination are not the primary drivers of the 290 surveyed human skin cancers in the COSMIC database, and that other lesions (e.g., various 291 types of photodimers) are the main contributors to the mutation catalogue of UV-induced skin 292 cancers. Another possible explanation is that with a small sample size of mutations, the high 293 degree of similarity in the SBS 2 and SBS 7a signatures confounds this analysis. By this logic, 294 some portion of the mutational signature identified as SBS 2 in our study may be the result of 295 the mutational processes associated with SBS 7a, which is found in multiple cancer types but is 296 most pronounced in skin cancers 14, 17 . Indeed, the SBS 7a signature contributes to 27% of the 297 mutations observed after sunlight exposure. 298
Activation of error-prone polymerases has been attributed to SBS 10b 14 , a signature that 299 is mostly found in colorectal and uterine cancers. In the present study, this signature was only 300 associated with X-ray mutations (49%). X-ray mutations show a high proportion of C>T 301 substitutions at the TCG motif (Supplementary Figure S4) , which is characteristic of the lacZ 302 normalized SBS 10b signature (Supplementary Figure S3 ). It is possible that there is an ionizing 303 radiation component to this signature. However, given previous work in this area, it is more 304 likely that the association between SBS 10b and X-ray SNVs is a result of error-prone 305 replication occurring in response to DNA damage. 306
The analysis of mutational signatures for the electromagnetic radiation agents provide 307 support for the ability of the expanded repertoire of COSMIC signatures to exploit subtle 308 differences in the mutation profiles to extract different mutational mechanisms. Using the 309 previous version of the COSMIC database, all three radiation types had a comparable 310 contribution from signature 7 (21-33%; data not shown). However, there are now four SBS 311 signatures (7a-7d) derived from the original signature 7 in the latest COSMIC database 15 , and of 312 these, only the SBS 7a signature contributes significantly to the mutation profile of sunlight. 313
Tobacco smoking is strongly associated with SBS 4, and this signature is commonly 314 found in the lung tumors of smokers. BaP is a major mutagenic component in tobacco smoke 21 315 and as expected, SBS 4 contributed the highest percentage (36%) to the mutation profile of 316
BaP. Interestingly, SBS4 was the only signature that contributed to the mutation profile of BaP 317 and accounted for 60% of the observed profile when using the previous version of the COSMIC 318 database (data not shown). However, using version 3 of the COSMIC database 15 , the 319 contribution of SBS 4 declined while we identified a second signature that contributed to the 320 BaP mutation profile. Specifically, we detected a significant contribution (27%) of the SBS 39 321 signature, which is one of the new signatures and currently has no known etiology. These 322 results suggest an overlap in the aetiology of these two signatures and that SBS 39 may be 323 associated with exposure to chemicals that induce bulky adducts. 324
The BaP mutation profile that we derived using our approach is consistent with previous 325 work in vivo 27 and in vitro 28 that demonstrated the presence of SBS 4 after exposure to BaP. 326
Indeed, the BaP mutation profile is consistent among the three studies (Pearson's correlation of 327 0.80 and 0.71 with the in vivo and in vitro profile, respectively). Remarkably, signatures SBS 24, 328 which has been associated with aflatoxin adducts, and SBS 29, which has been associated with 329 tobacco chewing, are strikingly similar to SBS 4 (Supplementary Figure S3 ). However, only SBS 330 4 strongly correlates with the BaP mutation data. This demonstrates the robustness of the 331 mutational signatures and the ability of TGR-NGS to correctly discriminate between similar 332 signatures that have different aetiologies. It also emphasizes the importance of the flanking 333 nucleotides to increasing the specificity of the signatures; this work demonstrates that 96-bp 334 signatures provide superior mechanistic information to standard mutation spectrum analysis. 335
NDMA was the only alkylating agent among those investigated that was associated with 336 an established COSMIC signature. About 50% of the NDMA mutation profile was explained by 337 the SBS 30 signature that has been associated with a deficiency in base excision repair. NDMA 338 is known to induce mostly 0 6 -and N 7 -methyl guanine adducts 34 , thus, a role of base excision 339 repair in the response to this chemical is expected. NDMA exposure was also enriched for SBS 340 11 (37%), inducing primarily C>T mutations at CpC motifs (Supplementary Figure S4 ). SBS 11 341 has been detected in melanomas and glioblastomas, and the mutation pattern of this signature 342 has been attributed to alkylating agent exposures, such as temozolomide and N-methyl-N'-nitro-343 N-nitrosoguanidine 17, 19 . These alkylating agents induce C>T mutations, mostly at CpC motifs, 344 and mutations at this motif are the four most common in the SBS 11 signature. The TGR 345 mutation data from our study are consistent with this expected mutation spectrum. 346
The SBS 11 signature was not enriched within the mutation spectrum of the two other 347 alkylating agents (i.e., ENU or PRC) in our mutation database. This is expected because these 348 compounds induce a very different mutation spectrum, causing primarily T>A mutations. These 349 differences demonstrate that SBS 11 is specific to a particular mechanism of alkylation (i.e., 350 target sites for the alkylation events) and that there is currently no COSMIC signature for 351 alkylating agents that target thymine. Further TGR-NGS analyses of alkylating agents may 352 refine our understanding regarding which specific alkylating agents or defective 353 alkyltransferases underlie the mechanisms associated with SBS 11. 354
The mutation profile obtained with ENU, demonstrating a slight preponderance of T>A 355 mutations over T>C mutations, is consistent (Pearson's coefficient = 0.71) with that obtained in 356 the bone marrow of gpt delta mice 27 , although the correlation is reduced when expanding the six 357 possible base pair alterations to the 96 possible mutation types (Pearson's coefficient = 0.49). 358 This is mostly due to a deficiency of T>C mutations at CTN motifs with respect to gpt delta mice. 359
Nevertheless, the similarity with the ENU mutation profile from gpt delta mice is greater than 360 that obtained in vitro with an induced pluripotent stem cell (iPSC) line (Pearson's coefficient = 361 0.30) where the ENU signature is dominated by T>C mutations 28 . These authors speculate that 362 the preponderance of T>C mutations after in vitro exposure to ENU is driven by the intrinsic 363 characteristics of DNA repair processes in iPSCs. 364
The mutation profile of CEDU, a nitrogenous base analog, closely matched the SBS 26 365 signature, which contributed to 80% of mutations in exposed animals. This is the highest 366 contribution of a COSMIC signature to any of the mutation profiles generated in this study. SBS 367 26 is one of the seven SBS signatures associated with defective mismatch repair, which is one 368 of the major repair pathways that deals with base analogs 55 . Due to the limited number of 369 mutations recovered in the CEDU study, the association between SBS 26 and CEDU should be 370 further tested. Also, considering that CEDU is similar in structure to existing halogenated uracil 371 analogs that serve as therapeutics (e.g., fluorouracil), attention should be given to these 372 compounds as possible contributors to the SBS 26 signature and associated cancers. 373
Among the agents tested in this study, TEM is the only one that is more effective at 374 inducing chromosomal structural aberrations than mutations. TEM is a trifunctional alkylating 375 agent that induced a strong micronucleus response while eliciting a weak mutagenic response 376 in the hematopoietic system 48 . Our analysis identified SBS 40 signature as a strong contributor 377 (32%) to the mutation profile of TEM. SBS 40 is one of those signatures that is not dominated 378 by any specific type of base pair alteration and does not have a proposed aetiology. Further 379 studies are needed to confirm whether SBS 40 signature is an indicator of a clastogenic mode 380 of action. 381
In summary, we demonstrated that lacZ transgene sequence data can be used, in 382 conjunction with established mutation signatures derived from COSMIC cancer data sets, to test 383 the hypothesis that a given class of mutagenic agents is linked with specific human cancers. 384
Moreover, COSMIC signature mining based on TGR mutation data sets can be used to 385 generate new hypotheses regarding the mutagenic mechanisms associated with human 386 cancers. This study presents a potential avenue through which mutation signature analysis can 387 be applied to in vivo experimental models, and the analyses employed to improve 388 understanding of mode of action. The analyses can also generate hypotheses regarding the 389 mutational mechanisms of uncharacterized chemicals. The in vivo TGR-NGS approach has 390 comparable sensitivity to whole genome approaches used for investigating the mutational 391 landscape of environmental agents 18, 19, 26, 28, 56 . However, by avoiding the orders-of-magnitude 392 higher cost of whole-genome sequencing, the in vivo TGR-NGS approach offers much higher-393 throughput for the testing of chemical mutagens. Overall, these results highlight that some 394 mutational signatures may have large environmental components and contribute to the growing 395 body of evidence that analyses of mutations spectra shortly after exposure has bearing on the 396 carcinogenic mechanism and the mutational profile observed in fully developed cancers. 397
398
MATERIALS AND METHODS
399
Animal Treatment 400
Male MutaMouse animals (6-15 weeks old; 6-8 per group) were exposed daily to either 401 100 mg/kg BaP, 5 mg/kg ENU, 25 mg/kg PRC or 2 mg/kg TEM by oral gavage for 28 days as The experimental protocol for enumerating lacZ mutants followed OECD guideline 488 57 . 415
Briefly, bone marrow was thawed and digested overnight with gentle shaking at 37 °C in 5 mL of 416 lysis buffer (10 mM Tris-HCl, pH 7.6, 10 mM ethylenediaminetetraacetic acid (EDTA), 100 mM 417 NaCl, 1 % sodium dodecyl sulfate (w/v), 1 mg/mL Proteinase K). High molecular weight 418 genomic DNA was isolated using phenol/chloroform extraction as described previously 42, 58 . The 419 isolated DNA was dissolved in 100 μL of TE buffer (10 mM Tris pH 7.6, 1 mM EDTA) and stored 420 at 4 °C for several days before use. The phenyl-β-D-galactopyranoside (P-gal) positive selection 421 assay 59 was used to identify lacZ mutants present in the DNA. Briefly, the λgt10lacZ construct 422 present in the genomic DNA was isolated and packaged into phage particles using the 423 Transpack™ lambda packaging system (Agilent, Mississauga, Ontario, Canada). The phages 424 were then mixed with E. coli (lacZ¯, galE¯, recA¯, pAA119¯ with galT and galK) 58 in order to 425 transfect the cells with the lacZ construct. E. coli were then plated on a selective media 426 containing 0.3% P-gal (w/v) and incubated overnight at 37 °C. Only E. coli receiving a mutant 427 copy of lacZ where the gene function is disrupted can form plaques on the P-gal medium, 428 because P-gal is toxic to galE¯ strains with a functional lacZ gene product 1 . Packaged phage 429 particles were concurrently plated on plates without P-gal (titre plates) to quantify the total 430 plaque-forming units to be used as the denominator in the mutant frequency calculation. 431
After enumeration, plaques from each individual sample were collected and pooled 432 together in microtubes containing autoclaved milliQ water (0.3 plaques/µL; mutants from 1 433 sample per tube). Mutant amplification and sequencing were done as described previously 8 . 434
Briefly, the mutant pools were boiled for 5 minutes and transferred to a PCR mastermix 435 containing a final concentration of 1X Q5 reaction buffer, 200 µM dNTPs, 0.5 µM Forward 436 primer (GGCTTTACACTTTATGCTTC), 0.5 µM Reverse Primer 437 (ACATAATGGATTTCCTTACG), and 1U Q5 enzyme (New England BioLabs Ltd., Whitby, 438 Ontario, Canada); the final volume of each PCR was 50 µL. To control for errors introduced 439 during PCR, each mutant pool was amplified twice as two separate technical replicates. The 440 following thermocycle program was used for amplification: 95 °C for 3 min; 30 cycles of 95 °C 441 for 45 s, 50 °C for 1 min, 72 °C for 4 min; final extension at 72 °C for 7 min. PCR products were 442 purified using the QIAquick PCR purification kit (Qiagen, Montreal, Quebec, Canada). 443 NGS libraries were built using the NEBNext® Fast DNA Library Prep Set for Ion 444
Torrent™. Each technical replicate had a unique barcoded adaptor ligated to the lacZ DNA 445 fragments allowing for many samples to be sequenced simultaneously (up to 96 libraries per 446 NGS run). Sequencing was performed using the Ion Chef™ workflow and Ion Proton™ system 447 with P1 chips. NGS reads were aligned to the lacZ gene using bowtie 2 (version 2.1.0) and read 448 depths for every possible mutation were quantified using samtools (version 0.1.19). Mutations 449 were called if, after background correction (determined by sequencing non-mutants), both 450 technical replicates had mutation read depths above threshold values (equal to at least 451 1/number of plaques in pool) 8 . To further filter the data in this study, if the mutation read depths 452 between two technical replicates varied by ≥50% then that mutation was removed from analysis. 453
Clonally expanded mutants were only counted as one mutation. 454 455
Published Sanger Sequencing Data 456
Published data came from studies where lacZ transgene mutants were sequenced and 457 the position and type of each mutation was reported (summarized in Supplementary Table S1 ). 458
Mutants were characterized from MutaMouse or LacZ Plasmid mice 60 . Some studies reported 459 the position of the mutation in the plasmid construct, while others reported the position in the 460 coding sequence. For consistency, the positional information was adjusted to reflect the position 461 of the mutation in the coding sequence of the lacZ gene. Furthermore, the reference sequence 462 of lacZ used for NGS has four variations 38 relative to the E. coli lacZ coding sequence 463 (Genbank: V00296.1) 61 , including a 15 bp insertion into codon 8. Thus, mutation positions were 464 also adjusted to reflect this where applicable (e.g., if LacZ Plasmid mice were used instead of 465 MutaMouse). No mutations were detected at or next to the variant positions in the LacZ Plasmid 466 motif. In contrast to NGS work, different tissues were used for these analyses (i.e., bone 467 marrow, brain, colon, germ cells, kidney, liver, skin, spleen, and stomach). Tissue sources are 468 noted in the results with the accompanying data. 469 470
Signature Analyses 471
The workflow used to do signature analyses are available as an RShiny web-application 472 (https://github.com/MarcBeal/HC-MSD/tree/master/lacZ_Mutations_COSMIC_Signatures). 473
Mutations for control and exposed samples (see metadata in Supplemental Material) were 474 imported into the R console 62 as VRanges using the package "VariantAnnotation" 63 with the lacZ 475 coding sequence as the reference FASTA file. To determine which of the COSMIC mutation 476 signatures best explained the observed lacZ mutant spectrum, the COSMIC mutation signature 477 weights, which are derived from human mutation data, were first normalized to lacZ trinucleotide 478 frequencies. This was done using the ratio of trinucleotide frequencies in lacZ to the 479 trinucleotide frequencies in the human genome ( Figure 3 ; the normalized signatures are shown 480
in Supplementary Figure S3 and the raw numbers in Supplementary Material). Analysis was 481 done this way (as opposed to converting lacZ mutation data themselves to human trinucleotide 482 frequencies) because the COSMIC signature are based on a much larger database, and 483 therefore, represent a more robust signal with less variance. Following normalization, each of 484 the 96 trinucleotide substitutions within each signature were represented as the relative 485 frequency (i.e., all values in a signature sum to 1) by dividing each normalized value by the sum 486 of all values for that signature. The trinucleotide mutation context (i.e., the nucleotide 487 immediately upstream and downstream of the mutation) was obtained with the 488 "mutationContext" function and converted to a motif matrix using the "motifMatrix" function (both 489 in the "SomaticSignatures" package 64 ). The motif matrix was then transposed to obtain the 490 required format, and finally decomposed into the constituent lacZ-normalized signatures using 491 the "whichSignatures" function from "deconstructSigs" 65 . The contribution of each identified 492 signature to the mutation data was reported as a fraction. If the sum of each signature did not 493 account for 100% of the mutation data, then the remainder was reported as the "residual". 494
In order to account for spontaneous mutations often present alongside induced 495 mutations, which is especially true for weak mutagens, we generated a signature for the 496 spontaneous mutation background using the mutations observed in control animals. This 497 included all control mutations characterized by NGS and Sanger sequencing. However, 498 spontaneous SNVs characterized by Sanger sequencing were heavily biased towards positions 499 1072, 1090, 1187, 1627, and 2374. Therefore, Sanger sequencing data at these 5 positions 500
were not used for deriving the control mutation signature. Signatures were plotted using 501 ggplot2 66 . 502 "Signature reconstruction" was then used to determine how well the combination of 503 normalized signatures, identified using the "whichSignatures" function, explain the mutation data 504 from the respective exposure groups. For example, if signatures 3 and 4 contributed 40% and 505 60% to the mutation profile of a compound, respectively, then the motif matrices for signatures 3 506 and 4 were multiplied by 0.4 and 0.6, respectively, and summed together. The reconstructed 507 signature was then compared against the motif matrices of the compound using Pearson 508
correlation. 509
Lastly, the contribution of individual signatures was further validated using Pearson 510 correlation. Specifically, each signature was compared against the respective 96-base context 511 mutation spectra from which the signature was identified. In the final results, COSMIC 512 signatures were only reported if the contribution was greater than the largest residual, and the 513 Pearson coefficient with the reconstructed signature was greater than 0.5. 514
515
Statistics 516
Statistical analyses were done using the R programming language 62 . Mutant frequencies 517 were compared between exposure groups and controls using generalized estimating equations 518 assuming a Poisson distribution for the error, as done previously 8 , using the geepack library 67 519 with outliers (1 in control, 1 in TEM) removed. Bonferonni correction for multiple comparisons 520 was used to adjust the threshold of significance. Mutation spectra of the chemical exposure 521 groups were compared against controls using mutation proportions. The standard error for the 522 mutation spectra was determined using error propagation. Significant differences in mutation 523 spectra between chemically induced mutants and spontaneous control mutants were 524 determined using Fisher's exact tests with Bonferroni correction for multiple comparisons (i.e., 525 across different chemical groups). To compare whole mutation spectra between control and 526 exposed groups, Fisher's exact tests were performed with Monte Carlo simulation with 10,000 527
replicates. Fisher's exact tests were also performed on 2 × 2 sub-tables for each mutation type. determination of mutant frequencies (Steps 1-2); sequencing of collected plaques and collection 790
1. Four chemicals were tested in-house against solvent controls using the TGR in vivo mutagenicity assay 2. Mutant plaques from controls and chemicalexposed mice were collected and pooled per individual 3. Mutant plaques were PCR amplified as 2 technical replicates, library prepped and sequenced on the Ion Proton Platform. SNVs were called and corrected for clonal expansion 4. Published Sanger sequencing data were compiled for 8 additional chemicals, plus controls, tested using the lacZ plasmid or MutaMouse mice 5. All sequencing data (Sanger and Ion Proton) were imported into the R console and trinucleotide mutation context were obtained using the "mutationContext" function 6. To compare human COSMIC signatures and lacZ mutation data, the COSMIC signatures were normalized to lacZ trinucleotide frequencies and each of the 96 trinucleotide substitutions were represented as relative frequency 7. The "deconstructSigs" package was used to identify COSMIC signatures that best describe the mutational fingerprint of chemical exposure 8. Identified signatures were multiplied by their respective contributions and used to reconstruct the mutational fingerprint of chemical exposure 9. Pearson correlation was used to determine how well reconstructed signature models compared to empirically-derived mutational fingerprint insertions, and deletions compared to control. In contrast, there is a lower proportion of T>C, 800 C>T, T>A, and T>G mutations than control. ENU, shown in green, has a higher proportion of 801 T>A mutations, while C>T, C>G, and deletions are lower. PRC, shown in purple, has a higher 802 proportion of T>A compared to control, and a marginally significant increase in T>C mutations 803 compared to control (P = 0.055). The mutation spectrum for TEM, shown in turquoise, is most 804 similar to that of the control, with the exception of a significant increase in the proportion of 805 insertions. ‡ P < 0.1, † P < 0.05, * P < 0.0001. ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC 
